Ignite Creation Date:
2025-12-24 @ 10:35 PM
Ignite Modification Date:
2025-12-30 @ 4:10 PM
Study NCT ID:
NCT04770935
Status:
COMPLETED
Last Update Posted:
2025-09-25
First Post:
2021-02-22
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
To Assess the Pharmacokinetics and Safety and Tolerability of Efanesoctocog Alfa (BIVV001)in Adults With Type 2N and 3 Von Willebrand Disease (VWD)
Sponsor:
Bioverativ, a Sanofi company
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-05-03
Start Date Type:
ACTUAL
Primary Completion Date:
2022-12-01
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-12-20
Completion Date Type:
ACTUAL
First Submit Date:
2021-02-22
First Submit QC Date:
None
Study First Post Date:
2021-02-25
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-09-21
Last Update Post Date:
2025-09-25
Last Update Post Date Type:
ESTIMATED